Abstract
Beta-lactam antibiotics constitute the agents most widely used against bacterial infections worldwide. Hence, the emergence and spread of beta-lactam hydrolyzing enzymes among pathogenic bacteria has proved to be one of the major medical issues especially when these enzymes inactivate carbapenems together with other beta-lactams. The prompt detection of beta-lactamases is important for therapeutic and epidemiological purposes therefore, various appropriate methodologies have been developed throughout the last decades. In the present overview, recent patents related to the detection of beta-lactamases and especially of carbapenemases are discussed.
Keywords: Beta-lactamases, carbapenemases, patents.
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Drug Safety
Current Drug Targets
Infectious Disorders - Drug Targets
Letters in Drug Design & Discovery
Current HIV Research
Current Drug Discovery Technologies
Anti-Infective Agents
Related Books
Frontiers in Clinical Drug Research: Anti-Infectives
Frontiers in Drug Design and Discovery
Frontiers in Anti-Infective Drug Discovery
Coronaviruses
Moving From COVID-19 Mathematical Models to Vaccine Design: Theory, Practice and Experiences
COVID-19: Effects in Comorbidities and Special Populations
An Update on SARS-CoV-2: Damage-response Framework, Potential Therapeutic Avenues and the Impact of Nanotechnology on COVID-19 Therapy
An Epidemiological Update on COVID -19
Frontiers in Cardiovascular Drug Discovery
Frontiers in Drug Design and Discovery
56